It's already been tried in controlled scientific testing.
One uncontrolled test doesn't prove anything. Looking at credible sources is a beginning.
The earliest formal clinical trials evaluating psilocybin in patients with cognitive decline began around 2021, led by researchers at the Johns Hopkins Center for Psychedelic & Consciousness Research evaluating its safety and efficacy for treating depression linked to early-stage Alzheimer's disease and mild cognitive impairment.
Johns Hopkins University Pilot Study: Initiated in March 2021 (estimated completion 2027), this pioneering trial tests synthetic psilocybin paired with psychological counseling to treat depression and improve quality of life in participants with early-stage Alzheimer’s disease or mild cognitive impairment.
Could psychedelics – drugs that alter the mind – be a treatment to help people with ADRD cope with their condition? Researchers at Johns Hopkins are trying to answer this question.
pennmemorycenter.org
UC Berkeley PLASTICITY Study: Launched to examine how psilocybin impacts brain plasticity, memory, and emotional regulation in healthy older adults (ages 60 to 85), establishing foundational safety and neuroimaging data for older cohorts.
In a new study, UC Berkeley researchers are investigating whether psilocybin can support healthy aging by boosting plasticity in the brains of older adults.
news.berkeley.edu
UCSF Trial on Aging and Biomarkers: Registered to analyze functional brain changes, electrical activity (EEG), and neuroinflammation markers in older adults relative to Alzheimer's disease pathology.
This Older Adults (50-90 Years) and Alzheimer's Disease study at UCSF is now recruiting people ages 50-85.
clinicaltrials.ucsf.edu
Notable Observations and Case Reports
• Advanced Alzheimer's Case Report: Published recently in 2026, a documented observational case of an octogenarian with advanced Alzheimer's disease given a high-potency supervised dose of psilocybin-containing mushrooms reported transient multi-domain functional recovery, including temporary lucid speech and restored continence.
Researchers heavily caution that this single, uncontrolled observation does not prove disease reversal and emphasize that rigorous clinical trials are mandatory.
BackgroundAdvanced Alzheimer’s disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter lar...
www.frontiersin.org
Relevant, credible research is needed!
Edited to improve content.
- Geowizard